Judge Rules Against AstraZeneca's Plea to Ban Crestor Generics

Jul 20, 2016

Reuters

A federal judge in Washington, D.C., ruled against AstraZeneca’s request for a temporary ban on Crestor generics. Unless there is an appeal, the ruling means generic drug manufacturers can now enter the U.S. market, according to a Reuters article.

Crestor reportedly generated more than $5 billion in global sales for AstraZeneca last year.

Sales of the name-brand drug could potentially drop 30 percent as cheaper alternatives become available, according to Bloomberg analyst estimates.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments